Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

The clinical success of radiolabeled somatostatin analogs in the diagnosis and therapy—“theranostics”—of tumors expressing the somatostatin subtype 2 receptor (SST(2)R) has paved the way for the development of a broader panel of peptide radioligands targeting different human tumors. This approach re...

Descripción completa

Detalles Bibliográficos
Autores principales: Nock, Berthold A., Kanellopoulos, Panagiotis, Joosten, Lieke, Mansi, Rosalba, Maina, Theodosia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222684/
https://www.ncbi.nlm.nih.gov/pubmed/37242457
http://dx.doi.org/10.3390/ph16050674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222684/
https://www.ncbi.nlm.nih.gov/pubmed/37242457
http://dx.doi.org/10.3390/ph16050674

Ejemplares similares